Recent developments in immunotherapy of acute myeloid leukemia

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

(2017) Frederick L. Locke et al.   MOLECULAR THERAPY

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute myeloid leukemia targets for bispecific antibodies

(2017) S S Hoseini et al.   Blood Cancer Journal

Dying a fiery death: pyroptosis in MDS

(2016) A. R. Walker   BLOOD

Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature

(2016) D. Kavanagh et al.   BLOOD

MYC/BCL2 double-hit lymphoma/leukemia mimicking acute leukemia at initial presentation

(2016) Z. Chen et al.   BLOOD

The growing world of CAR T cell trials: a systematic review

(2016) Astrid Holzinger et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Dendritic cell-based immunotherapy

(2016) Rachel L Sabado et al.   CELL RESEARCH

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

(2016) U. Reusch et al.   CLINICAL CANCER RESEARCH

A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells

(2016) Qing Ma et al.   CYTOTHERAPY

The emerging role of immune checkpoint inhibition in malignant lymphoma

(2016) Ida Hude et al.   HAEMATOLOGICA

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

(2016) Sergio Amadori et al.   JOURNAL OF CLINICAL ONCOLOGY

Engineering Hematopoietic Cells for Cancer Immunotherapy

(2016) Diana Resetca et al.   JOURNAL OF IMMUNOTHERAPY

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors

(2016) I Aldoss et al.   LEUKEMIA

High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity

(2016) R C Lynn et al.   LEUKEMIA

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors

(2016) Radhika Thokala et al.   PLoS One

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

(2016) J. Rosenblatt et al.   Science Translational Medicine

Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells

(2016) Claudia C. Roskopf et al.   Oncotarget

The emerging role of immune checkpoint inhibition in malignant lymphoma

(2016) Ida Hude et al.   HAEMATOLOGICA

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

(2016) E. Zah et al.   Cancer Immunology Research

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

(2015) Jessica R. McCombs et al.   AAPS Journal

Antibody-drug conjugates as novel anti-cancer chemotherapeutics

(2015) C. Peters et al.   BIOSCIENCE REPORTS

Bispecific antibodies

(2015) Roland E. Kontermann et al.   DRUG DISCOVERY TODAY

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

(2015) Thomas Köhnke et al.   Journal of Hematology & Oncology

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

(2015) N Daver et al.   LEUKEMIA

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

(2015) C Krupka et al.   LEUKEMIA

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

(2015) S S Kenderian et al.   LEUKEMIA

Abstract A203: CD3-EGFR bispecific Probody™ therapeutics induced tumor regressions and increased therapeutic window in preclinical studies

(2015) Sherry L. LaPorte et al.   MOLECULAR CANCER THERAPEUTICS

Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies

(2015) Gerhard Zugmaier et al.   MOLECULAR IMMUNOLOGY

Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia

(2015) Quan-shun Wang et al.   MOLECULAR THERAPY

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates

(2015) Gurunadh R. Chichili et al.   Science Translational Medicine

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Immunotherapy for Acute Myeloid Leukemia

(2015) Felix S. Lichtenegger et al.   SEMINARS IN HEMATOLOGY

Transpresentation of interleukin‑15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity

(2015) Johan Van den Bergh et al.   Oncotarget

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

(2015) Nestor Ramos et al.   Journal of Clinical Medicine

Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia

(2014) J. Loke et al.   ANNALS OF HEMATOLOGY

It takes a village

(2014) N. Winick   BLOOD

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

(2014) S. Gill et al.   BLOOD

New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia

(2014) Marion Subklewe et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Probody therapeutics for targeting antibodies to diseased tissue

(2014) Krishna R Polu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia

(2014) C. O'Hear et al.   HAEMATOLOGICA

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

(2014) Robert K Hills et al.   LANCET ONCOLOGY

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

(2014) I Pizzitola et al.   LEUKEMIA

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

(2014) A Ehninger et al.   Blood Cancer Journal

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

(2013) M. Casucci et al.   BLOOD

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

(2013) A. Mardiros et al.   BLOOD

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

(2013) C. Krupka et al.   BLOOD

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

(2013) S. Nand et al.   BLOOD

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

(2013) G. S. Laszlo et al.   BLOOD

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor

(2013) Sarah Tettamanti et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells

(2013) Y.-H. Chang et al.   CANCER RESEARCH

Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study

(2013) R. B. Walter et al.   HAEMATOLOGICA

Allogeneic Transplantation Versus Chemotherapy as Postremission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs Analysis

(2013) Matthias Stelljes et al.   JOURNAL OF CLINICAL ONCOLOGY

Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system

(2013) C Arndt et al.   LEUKEMIA

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

(2013) David S. Ritchie et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

(2013) E. Lanitis et al.   Cancer Immunology Research

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

(2012) G. Borthakur et al.   HAEMATOLOGICA

Current strategies in immunotherapy for acute myeloid leukemia

(2012) Felix S Lichtenegger et al.   Immunotherapy

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

(2012) M Aigner et al.   LEUKEMIA

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

(2012) Jan J. Cornelissen et al.   Nature Reviews Clinical Oncology

CD86 and IL-12p70 Are Key Players for T Helper 1 Polarization and Natural Killer Cell Activation by Toll-Like Receptor-Induced Dendritic Cells

(2012) Felix S. Lichtenegger et al.   PLoS One

DARTs take aim at BiTEs

(2011) C. Rader   BLOOD

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

(2011) P. A. Moore et al.   BLOOD

Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission

(2011) Barbara Beck et al.   Journal of Translational Medicine

Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen

(2010) S Peinert et al.   GENE THERAPY

Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075

(2010) S. Spranger et al.   JOURNAL OF IMMUNOLOGY

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

(2010) V. F. Van Tendeloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia

(2009) Deborah A. Thomas et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Persistence of CD33 expression at relapse in CD33+acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease

(2008) Patrice Chevallier et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH